Why there is no official protocol
The trials that made these drugs famous studied starting them, titrating up, and staying on. Leaving was an afterthought, measured mostly by accident when extensions watched what happened to people who stopped. The result, stated plainly in the 2026 literature: no evidence-based protocols currently guide GLP-1 de-escalation, and patients report improvising their own. One prescriber put it bluntly in a widely shared community thread: there is no weaning protocol. Your doctor is not hiding it. Medicine has not written it.
That gap does not mean nothing is known. It means the known things come from pharmacology, trial extensions, case series, and thousands of documented exits, and they assemble into a plan that a prescriber can supervise, even without an official flowchart.
Taper vs cold turkey: the honest scorecard
| Claim | Status |
|---|---|
| Stopping abruptly without support leads to major regain | Established. STEP-1 extension: about two-thirds of lost weight back within a year. SURMOUNT-4: 82% of stoppers gave back 25%+ of their loss. |
| Stepping down doses can hold weight in selected patients | Emerging. Feb 2026 Obesity case series: weight, body composition, and metabolic markers maintained through structured de-escalation. |
| Tapering with coaching can hold weight after full stop | Emerging. A Danish tapering-plus-behavioral-support cohort stayed weight-stable six months post-stop. |
| Tapering beats cold turkey for long-term weight | Plausible but unproven. Most clinicians favor it; no randomized trial has tested it. |
| About 45% of real-world discontinuers maintain or keep losing at 1 year | Established (Cleveland Clinic, ~8,000 patients). Maintainers exist at scale; structure separates them. |
Read that table twice and the pattern is clear: how you stop matters less than what is in place when you do. The taper changes the slope of the transition. The structure decides where you land.
What a taper actually changes
These molecules leave on a fixed clock: semaglutide's half-life is about 7 days, tirzepatide's about 5, and each dose is essentially gone after five half-lives. A taper cannot speed that up or slow it down. What it changes is the height you fall from. Stop from 2.4mg and the full appetite transition arrives in one window, roughly weeks 2 through 6 after the last shot. Step down over months and you meet the same transition in slices, each one smaller, with time to adjust your eating structure between steps.
You can see the fade after any dose, including each step of a taper, with the washout calculator. If the conversation with your prescriber is heading toward a lower ongoing dose rather than zero, the microdosing chart maps that territory and its evidence honestly.
The five things that actually predict keeping it off
- Expect the water jump. The scale rises 2 to 6 lbs in the first two weeks off. It is water and glycogen, not fat. People who know this coming treat it as data; people who don't often spiral in week one and abandon the plan before the real transition even starts.
- A protein floor, immediately. 25 to 40g per meal, anchored to your goal weight. Protein is the most satiating macro, it defends muscle, and for the first time in a long time your appetite will let you eat enough of it.
- Strength work, 2 to 3 short sessions a week. Muscle lost during rapid weight loss is the main reason regain lands as a worse body composition than baseline. Protein plus resistance training cut lean-mass loss dramatically in controlled research.
- Recalculate your targets. Off the drug, appetite intuition is gone and your body burns 300 to 500 fewer calories a day than before the loss. Numbers must replace the drug's signal, at least until a new normal forms.
- Watch the trend, not the day. Daily weigh-ins smoothed into a weekly trend catch drift at 4 lbs, when it is a course correction, instead of 20, when it feels like a verdict.
And plan for the food noise, don't white-knuckle it. It typically flickers back in weeks 2 to 3 and peaks in weeks 3 to 6. Have the 10-minute protocol ready before it arrives. Resolve is exactly the resource the transition drains; structure is what holds.
Questions to bring to your prescriber
- Given my dose and history, would you step me down or stop directly, and why?
- If we step down: what rung, for how long, and what are we watching to decide the next step?
- What weight-trend change would make you want to revisit the plan?
- Is a lower ongoing maintenance dose an option for me instead of zero?
- Which of my improvements (blood pressure, sugar, joints, sleep) should we re-check after stopping, and when?
- If it goes badly, what does restarting look like, and at what dose?
Bring your regimen and a weight trend to that appointment. Prescribers improvising without a protocol do their best work when handed a clean record instead of a vague summary.
Special cases with their own rules
- Surgery: anesthesia guidance requires holding GLP-1s before elective procedures because of aspiration risk. Your surgical team sets this schedule, not this page.
- Pregnancy: clinical guidance is to stop 1 to 2 months before trying to conceive. This is a planned, deadline-driven exit; run it with your OB.
- Forced off (insurance, supply, compounding shutdown): you did not choose this timeline and the injustice is real. Appeal, explore savings programs, try everything. And run the same five levers above in parallel, because they work regardless of why the medication ended.